Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff , Kirstine Brown‐Frandsen , Helen M. Colhoun , A. Michael Lincoff , Kirstine Brown‐Frandsen , Helen M. Colhoun , John Deanfield , Scott S. Emerson , Sille Esbjerg , Søren Hardt‐Lindberg , G. Kees Hovingh , Steven E. Kahn , Robert F. Kushner , Ildiko Lingvay , Tuğçe Kalaycı Oral , Marie Mide Michelsen , Jorge Plutzky , Christoffer W. Tornøe , Donna H. Ryan
2023 New England Journal of Medicine 1,860 citations

Abstract

In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).

Keywords

SemaglutideMedicinePlaceboHazard ratioInternal medicineMyocardial infarctionDulaglutideDiabetes mellitusDiscontinuationBody mass indexAdverse effectOverweightType 2 diabetesStroke (engine)Clinical endpointConfidence intervalRandomized controlled trialSurgeryLiraglutideEndocrinology

Affiliated Institutions

Related Publications

Publication Info

Year
2023
Type
article
Volume
389
Issue
24
Pages
2221-2232
Citations
1860
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1860
OpenAlex

Cite This

A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine , 389 (24) , 2221-2232. https://doi.org/10.1056/nejmoa2307563

Identifiers

DOI
10.1056/nejmoa2307563